Note 15 - Subsequent Event	6 Months Ended
Jun. 30, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	*NOTE 15:* SUBSEQUENT EVENT** On July 1, 2022, the Company entered into a letter agreement (the “Letter Agreement”) with a U.S. private company that is in the pre-clinical stage of developing novel Chimeric Antigen Receptor (CAR) T-cell therapies based on technology licensed from a leading U.S. cancer treatment and research institution (the “CAR-T Company”). The Letter Agreement requires that up until November 1, 2022 the CAR-T Company will (i) negotiate exclusively with the Company for the Company to acquire the CAR-T Company, and (ii) address certain matters related to personnel, operations and intellectual property. The Company paid $2,700 in July 2022 for the exclusive right to negotiate with the CAR-T Company. If a definitive agreement is not reached for the Company to acquire the CAR-T Company and if a specified material adverse event has not occurred, then the Company will pay an additional $2,000 for a 19.99% preferred stock equity interest in the CAR-T Company. The Company is under no obligation to complete the acquisition of the CAR-T Company and no assurance can be given that an acquisition will be completed on acceptable terms or at all.

Note 15 - Subsequent Event

6 Months Ended

Jun. 30, 2022

NOTE 15: SUBSEQUENT EVENT

On July 1, 2022, the Company entered into a letter agreement (the “Letter Agreement”) with a U.S. private company that is in the pre-clinical stage of developing novel Chimeric Antigen Receptor (CAR) T-cell therapies based on technology licensed from a leading U.S. cancer treatment and research institution (the “CAR-T Company”). The Letter Agreement requires that up until November 1, 2022 the CAR-T Company will (i) negotiate exclusively with the Company for the Company to acquire the CAR-T Company, and (ii) address certain matters related to personnel, operations and intellectual property. The Company paid $2,700 in July 2022 for the exclusive right to negotiate with the CAR-T Company. If a definitive agreement is not reached for the Company to acquire the CAR-T Company and if a specified material adverse event has not occurred, then the Company will pay an additional $2,000 for a 19.99% preferred stock equity interest in the CAR-T Company. The Company is under no obligation to complete the acquisition of the CAR-T Company and no assurance can be given that an acquisition will be completed on acceptable terms or at all.